Jeffrey W. Albers appointed President of Algeta US
Algeta ASA announced the appointment of Jeffrey W. Albers as President of Algeta US, the Company’s new US commercial operation. He takes up his position immediately and will join Algeta’s executive management team, reporting to President and CEO, Andrew Kay.
Mr. Albers will work closely with Algeta’s senior management as part of the executive management team to enable Algeta’s US commercial operations; the current plans for which include the phased building of a sales force and a marketing and medical affairs team ahead of the launch of Alpharadin (radium-223 chloride) for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases, pending approval.
Mr. Albers joins Algeta from Genzyme (Sanofi), where he spent the past seven years in senior commercial and corporate development positions, most recently as Vice President, US Hematology & Oncology Business. In this role, Mr. Albers had P&L responsibility for a USD 250m business that included multiple marketed products along with a pipeline of products to treat hematologic and solid tumor malignancies. He built and led a 135-person team spanning sales, operations, marketing, managed care, pricing and reimbursement, training and medical affairs. He was also involved in evaluating in-licensing opportunities. Mr. Albers played a key role in the successful US launch of Mozobil® and integrating Campath® and Leukine® into the portfolio (acquired from Bayer in 2009) involving a significant field force restructuring. After the acquisition of Genzyme by Sanofi he represented Genzyme on the US Oncology Integration Team. Prior to Genzyme, he spent five years (2000-2005) as an attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo, where he focused on life sciences transactional work. He has prior experience as a sales representative for Pfizer, Inc. Mr. Albers has a B.Sc. in Marketing from Indiana University, and a law degree (J.D.) and MBA from Georgetown University (Washington, DC).
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Machine Learning Speeds up Simulations in Material Science - Faster and More Accurate Methods Come in Useful in Various Applications from Energy Storage to Medicines
Sigma-Aldrich Joins RNAi Consortium
Faster, more cost-effective DNA test for crime scenes, disease diagnosis
Febit Receives European Union (EU) Patent for Synthesis of Minimal Genomes
Genetic_genealogy
Oxford Expression Technologies and Eden Biodesign Sign Co-marketing Agreement

TA Instruments – Waters LLC - Wilmslow, United Kingdom
Group B Streptococcus infection causes estimated 150,000 stillbirth & infant death

COVID-19: A potential treatment for loss of smell
